ATE157363T1 - 9-substituierte-8-unsubstituierte-9-deazaguanin - Google Patents

9-substituierte-8-unsubstituierte-9-deazaguanin

Info

Publication number
ATE157363T1
ATE157363T1 AT90906624T AT90906624T ATE157363T1 AT E157363 T1 ATE157363 T1 AT E157363T1 AT 90906624 T AT90906624 T AT 90906624T AT 90906624 T AT90906624 T AT 90906624T AT E157363 T1 ATE157363 T1 AT E157363T1
Authority
AT
Austria
Prior art keywords
alkyl
trifluoromethyl
image
represents hydrogen
deazaguanine
Prior art date
Application number
AT90906624T
Other languages
English (en)
Inventor
John A Secrist Iii
Mark David Erion
John A Montgomery
Steven E Ealick
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Application granted granted Critical
Publication of ATE157363T1 publication Critical patent/ATE157363T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT90906624T 1989-02-27 1990-02-27 9-substituierte-8-unsubstituierte-9-deazaguanin ATE157363T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31606389A 1989-02-27 1989-02-27

Publications (1)

Publication Number Publication Date
ATE157363T1 true ATE157363T1 (de) 1997-09-15

Family

ID=23227309

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90906624T ATE157363T1 (de) 1989-02-27 1990-02-27 9-substituierte-8-unsubstituierte-9-deazaguanin

Country Status (15)

Country Link
US (2) US5565463A (de)
EP (1) EP0460116B1 (de)
JP (1) JP2760364B2 (de)
KR (1) KR100208315B1 (de)
AT (1) ATE157363T1 (de)
AU (1) AU640649B2 (de)
CA (1) CA2047216C (de)
DE (1) DE69031337T2 (de)
DK (1) DK0460116T3 (de)
ES (1) ES2106732T3 (de)
FI (1) FI95259C (de)
HU (1) HU217870B (de)
NO (1) NO180049C (de)
RU (1) RU2093513C1 (de)
WO (1) WO1990010631A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0500653A4 (en) * 1989-10-31 1995-08-23 Biocryst Inc Inhibitors of purine nucleoside phosphorylase
US5726311A (en) * 1989-11-29 1998-03-10 Biocryst Pharmaceuticals, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo 3,2-d!pyrimidine and pharmaceutical uses and compositions containing the same
US5236926A (en) * 1992-02-03 1993-08-17 Warner-Lambert Company 9-substituted-8-halo or -8-hydroxy-9-deazaguanines as inhibitors or PNP for pharmaceutical compositions
WO1995001355A1 (en) 1993-06-30 1995-01-12 Biocryst Pharmaceuticals, Inc. 9-deazahypoxanthines as pnp inhibitors
US5650511A (en) * 1995-12-12 1997-07-22 Biocryst Pharmaceuticals, Inc. Process for the preparation of 9-deazaguanine derivatives
CA2288317A1 (en) * 1997-05-29 1998-12-03 Benjamin Biro Mugrage 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydro-pyrrolo¬3,2-d|pyrimidin-4-ones
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
US6174888B1 (en) 1998-05-28 2001-01-16 Novartis Ag 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydropyrrolo[3,2-D]pyrimidin-4-ones
EP1768662A2 (de) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immunstimulatoren kleiner moleküle und assays für deren nachweis
US7763257B2 (en) 2004-12-09 2010-07-27 Christina Juneau Compositions comprising transforming growth factor (TGF)-β1 and TGF-β2 in admixture of proteins obtained from dairy products
UA104579C2 (uk) 2007-12-10 2014-02-25 Байокрист Фармасьютикалз, Инк. Спосіб лікування раку кровотворної системи із застосуванням фородезину у комбінації з ритуксимабом
WO2014205199A2 (en) 2013-06-22 2014-12-24 Nitor Therapeutics Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
WO2020186187A1 (en) 2019-03-13 2020-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772606A (en) * 1985-08-22 1988-09-20 Warner-Lambert Company Purine derivatives
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
IE60433B1 (en) * 1986-08-26 1994-07-13 Warner Lambert Co Novel 9-deazaguanines
US4923872A (en) * 1986-08-26 1990-05-08 Warner-Lambert Co. Analogues of pyrrolo[3,2d]pyrimidin-4-ones
CA1294960C (en) * 1986-10-24 1992-01-28 Thomas C. Malone 7-deazaguanines as immunomodulators
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
DE58902899D1 (de) * 1988-12-14 1993-01-14 Ciba Geigy Ag 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.

Also Published As

Publication number Publication date
US5721240A (en) 1998-02-24
JPH04503675A (ja) 1992-07-02
FI914015A0 (fi) 1991-08-26
FI95259B (fi) 1995-09-29
HU217870B (hu) 2000-04-28
AU640649B2 (en) 1993-09-02
CA2047216C (en) 1999-03-30
US5565463A (en) 1996-10-15
EP0460116B1 (de) 1997-08-27
CA2047216A1 (en) 1990-08-28
ES2106732T3 (es) 1997-11-16
KR100208315B1 (ko) 1999-07-15
RU2093513C1 (ru) 1997-10-20
KR920701209A (ko) 1992-08-11
WO1990010631A1 (en) 1990-09-20
JP2760364B2 (ja) 1998-05-28
DE69031337T2 (de) 1998-03-05
DE69031337D1 (de) 1997-10-02
NO180049B (no) 1996-10-28
HUT58737A (en) 1992-03-30
EP0460116A4 (en) 1992-05-13
DK0460116T3 (da) 1998-03-30
FI95259C (fi) 1996-01-10
NO913332L (no) 1991-08-26
NO913332D0 (no) 1991-08-26
AU5524890A (en) 1990-10-09
NO180049C (no) 1997-02-05
EP0460116A1 (de) 1991-12-11

Similar Documents

Publication Publication Date Title
ATE157363T1 (de) 9-substituierte-8-unsubstituierte-9-deazaguanin
MX9203687A (es) Nuevos derivados de 6&-metilprednisolona, su obtencion y uso.
EP0258733A3 (en) Carboxamides carboxamides
DK426185A (da) Nucleosid- og purinderivater
DK691287A (da) 5-floururacilderivater
NO923226L (no) Nytt beta-fenylisoserinderivat, dets fremstilling og anvendelse
AU552310B2 (en) 4-aroylimidazolin-2-ones
ES2067780T3 (es) 2'-desoxi-2'-metilidenocitidina dihidrato, metodos para su produccion y composiciones.
MA24197A1 (fr) Nouvelles fungarrestines
ES460807A1 (es) Procedimiento para la produccion de compuestos de isoindoli-nona.
ES8303370A1 (es) "procedimiento para la preparacion de 1,1-dioxidos de 4-hidroxi-1,2-benzoisotiazol-3(2h)-ona"
GR3004911T3 (de)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee